Appointment(s)
· Programme Chair, NUS Centre for Cancer Research, N2CR, Yong Loo Lin School of Medicine
· Deputy Director, Cancer Science Institute of Singapore, NUS
· Deputy Director, National University Cancer Institute, Singapore, National University Hospital
· Professor, Department of Pharmacology & Department of Medicine, NUS
· Senior Consultant, Department of Hematology-Oncology, National University Cancer Institute, Singapore, National University Hospital
Degree(s)
MBBS (S’pore), MRCP (UK), MMed (Int Med), FAMS
Biography
Professor Goh Boon Cher is a clinician scientist trained in internal medicine and oncology whose research integrates clinical pharmacology, translational oncology, and precision medicine. His group investigates the pharmacogenomics of anticancer drugs, early-phase clinical trials, and the molecular mechanisms of drug resistance in head-and-neck and lung cancers. Through multi-omics approaches—including single-cell, spatial, and extracellular vesicle profiling—his laboratory aims to identify actionable biomarkers and novel therapeutic strategies to enhance treatment efficacy and overcome immune resistance.
Research Areas/Research Interest
Cancer pharmacology, drug development, head and neck cancer, functional genomics.
Phase I study of ZD9331 using a 5-day short infusion schedule. J Clin Oncol 2001; 19:1476-1484
Goh BC, Ratain MJ, Smith R, Bertucci D, Mani S, Vogelzang NJ, Schilsky RL, Hutchison M, Smith M, Averbuch S, Douglass E
Explaining inter-individual variability of docetaxel pharmacokinetics and pharmacodynamics in asians through phenotyping and genotyping strategies. J Clin Oncol 2002;20:3683-3690
Goh BC, Soo-Chin Lee, Ling-Zhi Wang, Lu Fan, Jia-Yi Guo, Jatinder Lamba, Erin Schuetz, Robert Lim, Hong-Liang Lim, Ai-Bee Ong, How-Sung Lee
Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. J Clin Oncol 2009;27(28):4718-4726
Chiung-Ing Wong, Tong-San Koh, Ross Soo, Septian Hartono, Choon-Hua Thng, Evelyn McKeegan, Wei-Peng Yong, Chien-Shing Chen, Soo-Chin Lee, John Wong, Robert Lim, Norita Sukri, Siew-Eng Lim, Ai-Bee Ong, Joyce Steinberg, Neeraj Gupta, Rajendra Pradhan, Rod Humerickhouse, Goh BC
Phase I and biomarker study of a novel inhibitor of STAT3 phophorylation, OPB-51602 in patients with refractory solid cancers. Ann Oncol 2015;26(5):998-1005
4. A L Wong, R. A. Soo, D. S. Tan, S. C. Lee, J. S. Lim, P. C. Marban, L. R. Kong, Y. J. Lee, L. Z. Wang, W. L. Thuya, R. Soong, M. Q. Yee, T. M. Chin, M. T. Cordero, B. R. Asuncion, B. Pang, S. Pervaiz, JL Hirpara, A. Sinha, W. W. Xu, M. Yuasa, T. Tsunoda, M. Motoyama, T. Yamauchi and Goh BC
Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation. Nat Commun. 2020 Apr 29;11(1):2086. doi: 10.1038/s41467-020-15608
Kong LR, Ong RW, Tan TZ, Mohamed Salleh NAB, Thangavelu M, Chan JV, Koh LYJ, Periyasamy G, Lau JA, Le TBU, Wang L, Lee M, Kannan S, Verma CS, Lim CM, Chng WJ, Lane DP, Venkitaraman A, Hung HT, Cheok CF, Goh BC
A common MET polymorphism harnesses HER2 signaling to drive aggressive squamous cell carcinoma. Nat Commun. 2020 Mar 25;11(1):1556. doi: 10.1038/s41467-020-15318-5
Kong LR, Mohamed Salleh NAB, Ong RW, Tan TZ, Syn NL, Goh RM, Fhu CW, Tan DSW, Iyer NG, Kannan S, Verma CS, Lim YC, Soo R, Ho J, Huang Y, Lim JSJ, Yan BJ, Nga ME, Lim SG, Koeffler HP, Lee SC, Kappei D, Hung HT, Goh BC
FAM3C in circulating tumor-derived extracellular vesicles promotes non-small cell lung cancer growth in secondary sites. Theranostics. 2023 Jan 1;13(2):621-638. doi: 10.7150/thno.72297
Thuya WL, Kong LR, Syn NL, Ding LW, Cheow ESH, Wong RTX, Wang T, Goh RMW, Song H, Jayasinghe MK, Le MT, Hu JC, Yong WP, Lee SC, Wong AL, Sethi G, Hung HT, Ho PC, Thiery JP, Sze SK, Guo T, Soo RA, Yang H, Lim YC, Wang L, Goh BC
Tumor-derived extracellular vesicles convey solute transporters to induce bioenergetic dependence shift contributing to treatment resistance. Theranostics. 2024 Sep 30;14(16):6350-6369. doi: 10.7150/thno.100374
Hirpara J, Thuya WL, Cheow SH, Fernando K, Eu JQ, Wang L, Wong AL, Fong ELS, Ali AB, Ding LW, Zhuoran W, Lim YC, Pervaiz S, Goh BC
Pembrolizumab with or without bevacizumab in platinum-resistant recurrent or metastatic nasopharyngeal carcinoma: a randomised, open-label, phase 2 trial. Lancet Oncol. 2025 Feb;26(2):175-186. doi: 10.1016/S1470-2045(24)00677-6
Wan-Qin Chong, Jia-Li Low, Joshua K Tay, Thi Bich Uyen Le, Grace Shi-Qing Goh, Hui-Lin Teo, Kenneth Sooi, Regina Tong-Xin Wong, Jens Samol, Ming-Yann Lim, Hao Li, Niranjan Shirgaonkar, Shumei Chia, Anil Gopinathan, Donovan Kum-Chuen Eu, Raymond King-Yin Tsang, Kwok-Seng Loh, Han-Chong Toh, Nicholas Syn, Li-Ren Kong, Ramanuj Dasgupta, Bee-Choo Tai, Yaw-Chyn Lim, Boon-Cher Goh
Integration of Antiangiogenic Therapy with Cisplatin and Gemcitabine Chemotherapy in Patients with Nasopharyngeal Carcinoma. Clin Cancer Res. 2020 Oct 15;26(20):5320-5328. doi: 10.1158/1078-0432.CCR-20-1727. Epub 2020 Aug 14. PMID: 32816944
Chong WQ, Lim CM, Sinha AK, Tan CS, Chan GHJ, Huang Y, Kumarakulasinghe NB, Sundar R, Jeyasekharan AD, Loh WS, Tay JK, Yadav K, Wang L, Wong AL, Kong LR, Soo RA, Lau JA, Soon YY, Goh RM, Ho FCH, Chong SM, Lee SC, Loh KS, Tai BC, Lim YC, Goh BC
